BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,089,838 | +104.3% | 130,676 | +181.2% | 0.04% | +40.0% |
Q4 2022 | $533,567 | -22.8% | 46,478 | -15.3% | 0.02% | +13.6% |
Q3 2022 | $691,000 | +9.0% | 54,871 | -6.4% | 0.02% | +22.2% |
Q2 2022 | $634,000 | -31.2% | 58,645 | +4.7% | 0.02% | 0.0% |
Q1 2022 | $921,000 | +22.8% | 56,014 | +3.0% | 0.02% | +20.0% |
Q4 2021 | $750,000 | -20.1% | 54,383 | -16.7% | 0.02% | -16.7% |
Q3 2021 | $939,000 | +15.6% | 65,312 | +24.6% | 0.02% | +38.5% |
Q2 2021 | $812,000 | +49.8% | 52,412 | -3.4% | 0.01% | +30.0% |
Q1 2021 | $542,000 | -15.8% | 54,272 | -36.8% | 0.01% | -28.6% |
Q4 2020 | $644,000 | +69.9% | 85,880 | -13.2% | 0.01% | +16.7% |
Q3 2020 | $379,000 | +56.6% | 98,949 | +103.3% | 0.01% | +33.3% |
Q2 2020 | $242,000 | – | 48,675 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |